ACSCEND Tool Detects Hidden Cancer Stem Cells to Curb Recurrence
Scientists at the SN Bose National Center for Basic Sciences and Ashoka University have developed a breakthrough diagnostic tool known as the 'AI-based Cancer Stem-like Cell Profiler and Neoplasm Deconvoluter', or ACSCEND. This artificial intelligence-powered system aims to solve the persistent challenge of identifying cancer stem-like cells that often hide within tumors. These specific cells are frequently responsible for cancer recurrence, a nightmare scenario for patients and oncologists alike. By identifying these cells early, clinicians can tailor treatments to eliminate the source of the cancer rather than just the symptoms. The tool represents a major shift in how medical professionals approach tumor analysis. Traditionally, biopsies provide a snapshot of a tumor, but they often miss the rare stem-like cells that possess the ability to survive standard chemotherapy and radiation. Officials said the ACSCEND tool processes complex biological data to map these elusive cells with precision. This development is expected to change the standard of care for patients who previously faced a high risk of their disease returning months or even years after initial treatment. • ACSCEND uses advanced algorithms to deconvolute complex tumor profiles. • Researchers confirmed the tool successfully distinguishes between aggressive stem-like cells and dormant tumor cells. • The project is a joint effort between the SN Bose National Center for Basic Sciences and Ashoka University. The economic impact of cancer in India is staggering, with industry reports indicating that families often spend upwards of ₹15 lakh ($17,800 USD) on treatment and long-term care. By reducing the rate of recurrence, this technology could significantly lower the financial burden on middle-class families. Experts noted that early detection of these cells allows for more targeted interventions, which are generally more cost-effective than managing advanced-stage recurring cancer. The team is currently working on scaling the technology for use in major hospital chains across Mumbai, Delhi, and Bengaluru.
Tackling the High Risk of Cancer Recurrence in Indian Patients
Recurrence remains the primary obstacle in the fight against cancer in India. Many patients show initial recovery, only to face a relapse due to residual cancer stem cells that evade standard detection methods. Medical professionals explain that these cells exist in a state of relative dormancy, making them resistant to traditional cytotoxic therapies. The ACSCEND tool changes the equation by providing a detailed map of the tumor's cellular composition before a treatment plan is finalized. In India, where late-stage diagnosis is common, the ability to predict the risk of recurrence is a game-changer. Sources confirmed that the AI model can analyze biopsy samples to estimate the likelihood of a patient needing more aggressive therapy upfront. This prevents the 'wait and see' approach that often leaves patients vulnerable to a return of the disease. By integrating this AI tool into pathology labs, hospitals can provide personalized treatment regimens that were previously out of reach for most patients. The emotional toll of a cancer relapse often outweighs the physical struggle. Families in India frequently report the psychological strain of watching a loved one undergo multiple rounds of treatment. With this new technology, doctors can potentially minimize the number of unnecessary treatment cycles. Experts stated that the goal is to make cancer a manageable condition rather than a life-altering crisis. The integration of such AI tools is expected to become a standard practice in major metropolitan hospitals by the end of 2027.
Global Rise of Antibody-Drug Conjugates in Modern Oncology
While AI is making strides in detection, the broader field of oncology is seeing a surge in the use of Antibody-Drug Conjugates (ADCs). These treatments act like 'guided missiles,' delivering potent drugs directly to cancer cells while sparing healthy tissue. Globally, according to industry reports, 23 ADCs have received regulatory approval, with 16 of those authorized in the United States. Hundreds more are currently in various stages of development, turning once-untreatable forms of lung, breast, and bladder cancer into manageable chronic conditions. The American Association for Cancer Research (AACR) 2026 Progress Report highlights the effectiveness of these therapies. By combining the precision of antibodies with the killing power of chemotherapy, ADCs drastically reduce the side effects that have historically plagued cancer patients. In India, access to these drugs remains a challenge due to high costs, often reaching ₹2 lakh ($2,380 USD) per dose. However, as more domestic manufacturers begin to explore localized production, the cost is expected to decrease over the next three years. • 23 ADCs are currently approved globally for cancer treatment. • 16 of these approved therapies are available in the United States market. • ADCs are effectively converting terminal cancer cases into chronic, manageable illnesses. The shift toward precision medicine is undeniable. Hospitals in India are already seeing a demand for therapies that offer fewer side effects. As the technology matures, the combination of AI-based detection—like the ACSCEND tool—and targeted therapies like ADCs will likely define the next decade of cancer care. This dual approach ensures that clinicians not only identify the right target but also use the most effective weapon available.
Israeli Researchers Target BRCA-Mutant Cancers with AI
The use of artificial intelligence is not limited to India. Researchers in Israel are also harnessing AI to transform the diagnosis and treatment of complex cancers, particularly those linked to BRCA mutations. Alan Herman, executive director of the Israel Cancer Research Fund (ICRF), noted that BRCA-mutant cancers—especially breast and pancreatic cancer—remain among the most urgent challenges in oncology. He stated that AI is opening doors that traditional research methods simply could not reach. The AI models developed in Israel focus on identifying patterns in genetic data that correlate with high-risk mutations. By analyzing vast datasets, these tools can predict how a patient's cancer might respond to specific drugs, allowing for a more customized approach. This mirrors the work being done in India, proving that the global scientific community is moving toward a unified, technology-driven front against malignancy. The ability to share these findings across borders is accelerating the pace of innovation significantly. For Indian patients with a family history of breast cancer, this research is particularly relevant. Genetic testing, coupled with AI-driven risk assessment, is becoming more accessible in cities like Hyderabad and Chennai. Experts pointed out that the collaboration between international research bodies and local institutions is essential for validating these AI tools across diverse populations. The goal is to ensure that these technologies work as effectively in India as they do in the West, accounting for the unique genetic profiles of the local population.
NVIDIA and the Evolution of Clinical Decision Support Software
Technology giants are also entering the oncology space with tools designed to assist radiologists and oncologists. NVIDIA has developed WRRisk, a clinical decision support software that estimates a patient's long-term risk of developing breast cancer. This tool uses AI to analyze mammography images, helping radiologists detect subtle signs of cancer that might be missed during routine screenings. The software acts as a second set of eyes, providing a layer of security for both the patient and the physician. The company is currently researching a new generation of AI for mammography that aims to improve detection rates even further. This is especially important in India, where government figures show the ratio of radiologists to the population is low. By automating the initial screening process, AI tools can help prioritize patients who need urgent attention, ensuring that limited medical resources are used where they are needed most. This efficiency is critical for public health initiatives aimed at early detection. • WRRisk software provides long-term risk assessment for breast cancer patients. • AI-driven mammography tools are designed to reduce the workload of radiologists. • Early detection through AI screening can significantly improve survival rates for breast cancer. The implementation of such software in Indian diagnostic centers could be transformative. While the initial investment in technology is high, the long-term savings in healthcare costs are substantial. Experts noted that as these systems become more integrated with hospital databases, the speed of diagnosis will increase, allowing for earlier intervention and better patient outcomes.
Future Prospects for Cancer Care in India's Healthcare Sector
The integration of AI into cancer care is not a distant dream; it is happening now. With tools like ACSCEND, the future of oncology in India looks increasingly precise and patient-centered. As hospitals continue to adopt these technologies, the focus will shift from reactive treatment to proactive management. The ability to detect cancer stem cells early and use targeted therapies will likely become the standard of care within the next five years. However, the success of these innovations depends on infrastructure and training. Medical professionals must be upskilled to work alongside AI, and hospitals need to invest in the necessary computing power. Government initiatives, such as the Ayushman Bharat scheme, could play a role in subsidizing the use of these advanced diagnostic tools for the economically disadvantaged. Sources confirmed that discussions are underway to incorporate AI-based screening into state-run health programs. Looking ahead, the synergy between global research and local ingenuity will be the driving force of progress. As cancer becomes more understood at the molecular level, the tools available to doctors will only become more refined. The ultimate goal remains clear: to ensure that every patient, regardless of their background, has access to the best possible care. With the current momentum in AI development, that goal is closer than ever before. The next few years will likely see a significant decline in mortality rates for cancers that were once considered death sentences.